Navigation Links
What should be the goal of treatment in metastatic breast cancer?
Date:3/24/2010

This release is available in Spanish.

Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Wednesday). This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.

Dr. Amir Sheik-Yousouf, a resident physician in the Department of Internal Medicine at University of Toronto, Canada, working under the supervision of Dr. Sunil Verma, Chair of Breast Medical Oncology at Sunnybrook Odette Cancer Centre, Toronto, set out to look at what patients and doctors thought were the most important endpoints in incurable metastatic breast cancer, and what degree of benefit from their treatment should be considered to be important. The researchers say that, to their knowledge, this is the first time that the views of these two groups on such a question have been studied.

"We found that patients and doctors held very different views," says Dr. Sheik-Yousouf. "Our research shows that it is essential to have a thorough discussion of treatment goals with patients they expect a lot from the new therapies that are being developed but need also to understand that many of them are associated with only marginal improvements in survival."

The researchers surveyed 28 breast oncologists and 52 patients with metastatic breast cancer. Among the doctors, 52% believed that overall survival was the most important endpoint to be considered when choosing a treatment, and 48% believed that the most important outcome would be progression-free survival; 48% thought that that the minimum meaningful improvement in overall survival was four to six months, and 44% believed that a two to four month improvement in survival was meaningful.

Sixty percent of the oncologists surveyed believed that their patients also considered an improvement in overall survival to be the most important endpoint. The patients agreed, with 88% feeling that the primary goal of their treatment was to prolong life. However, when it came to the length of time of that survival, major differences with the doctors emerged, with 46% of patients thinking that only more than 12 months additional survival would make taking a treatment worthwhile for them; 17% thought that an extra 10-12 months would be acceptable, and only 10% thought that one to two months additional survival would be the minimal acceptable improvement.

Sixty-three percent of patients also believed that slowing tumour growth was a goal of treatment, and shrinking tumour burden and improving quality of life were also important to 62% of them; 17% thought shrinking tumour size was the most important goal of treatment. Fifty percent felt that improving symptoms and pain were other important therapeutic goals. Among the doctors, 36% believed that, after overall survival, overall quality of life would be the second most important factor to patients with metastatic breast cancer.

"This was only a small study and needs to be followed up on a larger scale," says Dr. Sheik-Yousouf. "However, the survey highlights major differences in the expectations of the outcome of treatment of metastatic breast cancer between oncologists and patients. We need not only to improve the way we discuss treatment options with patients, but also to ensure that clinical trials of new drugs are designed to meet the expectations of patients and doctors alike. We hope that by sharing the results of our study with our peers, industry, and government we may be able help them better develop new trials and guide their efforts in the approval and funding of new drugs for cancer."


'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Pentagon and Congress should act quickly to end gay military ban, APA says
2. Repeat of Fire Tragedy in Chicago High-Rise Should Have Been Prevented
3. Women should be allowed to eat, drink during labor: Queens University researcher
4. Transparency Should Not Be a Luxury; It Is a Matter of Life and Death: What Purchasers and Consumers Can Do
5. SIRIUS XM to Broadcast Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy
6. Emotions should be taken seriously
7. Going to the gym shouldnt be a workout for your eardrums
8. Should HPV Test Replace the Pap Smear?
9. Shoulder Repair Technique Borrows From Cadavers
10. Patients With Pacemakers Should Avoid MRI Scans
11. Who Should Deliver Your Baby? New Tool Helps Expectant Parents Choose Their Health Care Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... This week the The Voss Law Firm celebrates ... Bill Voss, the firm grew quickly and has built a reputation for excellence, trust, ... get the money they deserve from their insurance companies. , The Voss Law ...
(Date:8/23/2017)... DC (PRWEB) , ... August 23, 2017 , ... ... Oxygen Therapy continues to prove the safety and efficacy of HBOT in treating ... clinics across the US, points to research showing the similarities of the wounds ...
(Date:8/23/2017)... ... August 23, 2017 , ... PreCheck, Inc., ... 2017 Inc. 5000 with a three-year sales growth of 49 percent . ... and comprises the most comprehensive look at America’s independent entrepreneurs. This represents PreCheck’s ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... ... August 23, 2017 , ... A new literature review ... , points out that therapeutic modalities (physical therapy) is an important part of ... report, a wider scope of physical therapy options is showing promising results and ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017   Mostyn Law and Gulf Coast Regional ... Texas . The Mostyn Law family has had ... That is why Mostyn Law is partnering with Gulf ... show its appreciation. Blood supplies are running low. Gulf ... of hospital needs in August. That is why the blood center ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology: